Invention Grant
- Patent Title: Edaravone suspension for oral administration
-
Application No.: US17213501Application Date: 2021-03-26
-
Publication No.: US11241416B2Publication Date: 2022-02-08
- Inventor: Tetsuo Hayama , Tomohiro Takahashi , Tomoyuki Omura , Kouji Hayashi , Munetomo Matsuda , Tadashi Miyazawa
- Applicant: MITSUBISHI TANABE PHARMA CORPORATION
- Applicant Address: JP Osaka
- Assignee: MITSUBISHI TANABE PHARMA CORPORATION
- Current Assignee: MITSUBISHI TANABE PHARMA CORPORATION
- Current Assignee Address: JP Osaka
- Agency: Oblon, McClelland, Maier & Neustadt, L.L.P.
- Priority: JPJP2018-207646 20181102
- Main IPC: A61K31/4152
- IPC: A61K31/4152 ; A61K9/16 ; A61P21/00 ; A61K9/00 ; A61K47/32 ; A61K47/36
Abstract:
An edaravone suspension for human oral administration includes edaravone particles, a dispersant, and water.
Public/Granted literature
- US20210212990A1 EDARAVONE SUSPENSION FOR ORAL ADMINISTRATION Public/Granted day:2021-07-15
Information query
IPC分类:
